These observations, along with the synergistic effect of the alpelisib-AZD4547 combination, provide crucial insights into the molecular basis of alpelisib resistance and highlight potential strategies to overcome it by co-targeting PI3K and FGFR1 signaling in FGFR1-overexpressing breast cancer cells. Here, FGFR1 is linked to breast carcinoma.